The need for novel approaches to HIV-1 vaccine development

The study enrolled 2636 women aged 18–35 years without HIV-1 or HIV-2 from multiple hospital sites in sub-Saharan Africa between 2017 and 2019. [...]over the past decade, the field has started to work on a so-called rational approach to HIV-1 vaccine design. Despite the multitude of promising approaches, the induction of high and protective titers of one or more broadly neutralising antibodies will most probably need a whole set of immunogens administered over an extended period (figure). [...]it is imperative that the HIV vaccine development field convinces shareholders and funding agencies that studies such as the Imbokodo trial do not mark the end of the search for an HIV-1 vaccine.